Tokyo, Japan

Kazuyoshi Obitsu

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 22(Granted Patents)


Location History:

  • Tsukuba, JP (2009)
  • Chuo-ku, JP (2010 - 2011)
  • Tokyo, JP (2008 - 2019)

Company Filing History:


Years Active: 2008-2019

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Kazuyoshi Obitsu: Innovator in Pharmaceutical Chemistry

Introduction

Kazuyoshi Obitsu is a prominent inventor based in Tokyo, Japan, known for his significant contributions to pharmaceutical chemistry. He holds a total of seven patents, showcasing his innovative approach to drug development and production methods.

Latest Patents

One of his latest patents involves a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound. This compound exhibits superior agonistic activity to the arginine vasopressin V2 receptor, making it a valuable active ingredient for pharmaceutical compositions aimed at preventing and treating various urinary disorders. The production method he developed is notable for its efficiency, featuring fewer steps, higher yields, and lower costs compared to existing methods in the field.

Career Highlights

Kazuyoshi Obitsu has worked with notable companies in the pharmaceutical industry, including Astellas Pharma GmbH and Tacurion. His experience in these organizations has allowed him to refine his skills and contribute to advancements in medication production.

Collaborations

He has collaborated with esteemed colleagues such as Souichirou Kawazoe and Takahiro Akiba, further enhancing his research and development efforts in the pharmaceutical sector.

Conclusion

Kazuyoshi Obitsu's innovative work in pharmaceutical chemistry, particularly his recent patents, underscores his role as a key figure in the development of effective medical treatments. His contributions continue to impact the industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…